Former NFL star diagnosed at 39 reveals ALS's 90% sporadic toll

For healthcare providers and health IT innovators, Chris Johnson’s story is a real-world illustration of the relentless progression of ALS and the gaps in chronic disease management. From a man who could lift his children to one who can only communicate with the movement of his eyes, the 12-month decline demonstrates why multidisciplinary care models, remote monitoring, and cutting-edge assistive devices must become the standard—not the exception—for neurodegenerative diseases.

Former NFL star Chris Johnson, a one-time 2,000-yard rusher and one of the most electrifying running backs of his generation, has revealed he is battling amyotrophic lateral sclerosis (ALS). In a poignant interview on Good Morning America that aired June 29, 2026, the 40-year-old Johnson, accompanied by his wife Brittany, disclosed that he received the diagnosis in 2025 at age 39 after herculean declines in his physical abilities. The announcement has cast a harsh light on the cruel and rapid nature of ALS, a progressive neurodegenerative disease that robs patients of muscle control, speech, and ultimately the ability to breathe.

“

On the caregiver front, the financial and emotional toll is enormous; a study in Neurology found mean annual costs exceeding $70,000 per patient, often borne by families.

Johnson’s story is a heartbreaking case study in the disease’s devastating timeline. He described being in peak physical condition just over a year ago—exercising daily, chasing his four children, lifting his seven-year-old daughter to blow out birthday candles. Today, he communicates through a speech-generating device he controls with his eyes, no longer able to speak or even hold his children. That precipitous decline—from a world-class athlete to a man entirely dependent on assistive technology—underscores the unforgiving speed with which sporadic ALS, the form affecting Johnson and roughly 90% of all ALS patients, can dismantle a life.

Medically, ALS remains an area of profound unmet need. The Mayo Clinic describes it as a nervous system disease attacking motor neurons in the brain and spinal cord. There is no cure, and the handful of FDA-approved drugs—such as riluzole and edaravone—offer only modest benefits, extending survival by a matter of months rather than years. Johnson recalled the grim moment his doctors delivered the diagnosis after three rounds of testing: ‘They told us about a medication that might extend life by a few months. Then they told us to get our affairs in order.’ That exchange encapsulates the stark reality facing the roughly 5,000 Americans diagnosed with ALS each year.

The implications for the healthcare system are vast. Johnson’s rapid deterioration highlights the critical need for multidisciplinary ALS care—neurology, pulmonology, speech therapy, physical and occupational therapy—and for robust payer coverage of life-sustaining equipment like eye-tracking communication devices, ventilators, and power wheelchairs. Health IT solutions that enable remote monitoring of respiratory function and early intervention can be transformative, and the story may accelerate telehealth adoption for neurodegenerative disease management. On the caregiver front, the financial and emotional toll is enormous; a study in Neurology found mean annual costs exceeding $70,000 per patient, often borne by families.